Non-24-hour sleep-wake syndrome

Summary

Non-24-hour sleep-wake syndrome (MONDO:0019137) is a disease and 9 clinical trials. Top therapeutic interventions include tasimelteon and melatonin. A subtype of circadian rhythm sleep disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 5
• Clinical trials: 9

Clinical features

Signs & symptoms

Clinical features (HPO)

5 HPO clinical features (Orphanet curated; top 5 by frequency):

HPO ID	Term	Frequency
HP:0000618	Blindness	Frequent (30-79%)
HP:0000716	Depression	Frequent (30-79%)
HP:0001262	Excessive daytime somnolence	Frequent (30-79%)
HP:0012689	Abnormal pineal melatonin secretion	Frequent (30-79%)
HP:0025406	Asthenia	Frequent (30-79%)

Identifiers

Disease identifiers

Field	Value
Canonical name	non-24-hour sleep-wake syndrome
Mondo ID	MONDO:0019137
Orphanet	73267
ICD-10-CM	G47.24
SNOMED CT	230496009
UMLS	C0751759
MedGen	148383
GARD	0010949
NORD	1511
Is cancer (heuristic)	no

Also known as: circadian rhythm sleep disorder, free running type · circadian rhythm sleep disorder, free-running type · hypernychthemeral syndrome · non 24 hour sleep wake disorder · non-24 · Non-24-Hour Sleep-Wake Disorder

Disease family

This is a subtype of circadian rhythm sleep disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › sleep disorder › sleep-wake disorder › circadian rhythm sleep disorder › non-24-hour sleep-wake syndrome

Related subtypes (7): advanced sleep phase syndrome, rapid eye movement sleep disorder, circadian rhythm sleep disorder, delayed sleep phase type, circadian rhythm sleep disorder, advanced sleep phase type, circadian rhythm sleep disorder, irregular sleep wake type, circadian rhythm sleep disorder, jet lag type, circadian rhythm sleep disorder, shift work type

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	4
Not specified	2
PHASE4	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02130999	PHASE4	COMPLETED	Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)
NCT01163032	PHASE3	COMPLETED	Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder
NCT01218789	PHASE3	UNKNOWN	Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception
NCT01429116	PHASE3	COMPLETED	Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception
NCT01430754	PHASE3	COMPLETED	Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder
NCT00972075	PHASE2	COMPLETED	Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects
NCT02776215	PHASE1	COMPLETED	Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents
NCT03956745	Not specified	TERMINATED	Biomarkers for Circadian Timing in Healthy Adults
NCT03980340	Not specified	TERMINATED	Breath Biomarkers for Sleep Loss and Circadian Timing

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TASIMELTEON	4	5
MELATONIN	4	1